What are the recommended colchicine doses for an adult with acute gout flare, gout prophylaxis, familial Mediterranean fever, and acute pericarditis, and how should the dose be adjusted for renal or hepatic impairment, elderly patients, interacting drugs, and pediatric patients?

Colchicine Dosing Recommendations

Acute Gout Flare

For acute gout, administer colchicine 1.2 mg at the first sign of flare, followed by 0.6 mg one hour later (total 1.8 mg), then after a 12-hour pause resume 0.6 mg once or twice daily until the attack resolves. 1, 2, 3

Critical Timing Considerations

• Start treatment within 12 hours of symptom onset for maximum efficacy 3
• Do not initiate colchicine after 36 hours from symptom onset—efficacy drops sharply beyond this window 1, 2, 3
• Patients should be educated to self-medicate at the first warning symptoms using a "pill in the pocket" approach 3

Dose Adjustments for Renal Impairment

• Mild-to-moderate renal impairment (CrCl 30–80 mL/min): Use standard acute dosing (1.2 mg followed by 0.6 mg one hour later) with close monitoring; reduce prophylactic dose to 0.6 mg once daily 1
• Severe renal impairment (CrCl <30 mL/min): Maximum single dose of 0.6 mg with no repeat for at least 2 weeks—colchicine is essentially contraindicated in this population 2, 3

Absolute Contraindications

• Concurrent use of strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil), especially with any renal or hepatic impairment—risk of fatal toxicity 1, 3, 4
• Severe renal impairment (eGFR <30 mL/min) due to risk of fatal toxicity 1, 3

---

Gout Prophylaxis (When Starting Urate-Lowering Therapy)

Initiate colchicine 0.6 mg once or twice daily concurrently with the first dose of allopurinol or febuxostat, and continue for at least 6 months. 1, 2

Duration of Prophylaxis

• Minimum duration: 6 months 1, 2
• If no tophi present: Continue for 3 months after achieving target serum urate <6 mg/dL 1, 2
• If tophi present: Continue for 6 months after achieving target serum urate <6 mg/dL 1, 2

Dose Adjustments for Renal Impairment

• Mild-to-moderate renal impairment (CrCl 30–80 mL/min): Reduce to 0.6 mg once daily 1
• Severe renal impairment (CrCl <30 mL/min or eGFR 15–29 mL/min): Reduce to 0.3 mg once daily with close monitoring 2

Alternative Prophylaxis Options

• If colchicine contraindicated: Use low-dose NSAID plus proton-pump inhibitor (e.g., naproxen 250 mg twice daily with omeprazole 20 mg daily) or low-dose prednisone ≤10 mg/day 1, 2

---

Familial Mediterranean Fever (FMF)

Start colchicine as soon as clinical diagnosis is made; titrate dose based on age, response, and tolerance. 5

Pediatric Dosing

• Children <5 years: Start 0.5 mg/day (≤0.6 mg/day if tablets contain 0.6 mg); maximum 1.2 mg/day 5
• Children 5–10 years: Start 0.5–1.0 mg/day; maximum 1.8 mg/day 5
• Children >10 years: Start 1.0–1.5 mg/day; maximum 2 mg/day 5

Adult Dosing

• Starting dose: 1.0–1.5 mg/day 5
• Maximum dose: 3 mg/day 5
• Increase dose gradually (no more frequently than weekly) to control attacks and reduce subclinical inflammation 5

Dosing Frequency

• Can be given once or twice daily depending on adherence and tolerance 5
• Single daily dosing may be associated with more gastrointestinal intolerance 5

Monitoring and Dose Adjustments

• Monitor CRP, SAA, or both every 3 months during dose escalation 5
• In patients with decreased renal function, monitor CPK and signs of colchicine toxicity carefully; reduce dose accordingly 5
• If liver enzymes exceed 2× upper limit of normal, reduce colchicine dose and investigate further 5

Resistance Definition

• Colchicine resistance: ≥1 attack per month over 3 months despite maximum tolerated dose, or persistent subclinical inflammation 5
• Consider IL-1 inhibitors (anakinra, canakinumab, rilonacept) for resistant cases 5

---

Acute Pericarditis

For acute pericarditis, colchicine dosing follows similar principles to acute gout management, though specific pericarditis guidelines are not provided in the evidence. Based on general colchicine pharmacology, typical dosing would be weight-based: 0.5–0.6 mg twice daily for patients >70 kg, or 0.5–0.6 mg once daily for patients <70 kg, continued for 3 months. 6, 7

---

Drug Interactions and Special Populations

CYP3A4 and P-glycoprotein Inhibitors

• Strong inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil): Absolute contraindication to colchicine, especially with any renal or hepatic impairment 1, 3, 4
• Moderate inhibitors: Require dose reduction 2, 4
• Grapefruit juice can increase colchicine concentrations 4

Hepatic Impairment

• Reduce dose in hepatic dysfunction 5, 7
• Monitor liver enzymes regularly; if >2× upper limit of normal, reduce colchicine and investigate 5

Elderly Patients

• Use caution due to increased risk of adverse effects 1
• Consider lower starting doses and slower titration 7

Pregnancy and Lactation

• Do not discontinue colchicine during conception, pregnancy, or lactation—current evidence does not justify amniocentesis 5
• Men generally do not need to stop colchicine prior to conception; temporary dose reduction may be needed only in rare cases of proven colchicine-related azoospermia or oligospermia 5
• Colchicine crosses the placenta but shows no evidence of fetal toxicity 4
• Colchicine is excreted in breast milk but considered compatible with lactation 4

Concurrent Statin Therapy

• Monitor for neurotoxicity and myotoxicity, especially in patients with renal impairment 2, 4

---

Common Pitfalls to Avoid

• Never use obsolete high-dose regimens (0.5 mg every 2 hours until relief)—they cause severe diarrhea in 77–100% of patients without added benefit 1
• Do not combine colchicine with strong CYP3A4/P-gp inhibitors in patients with any renal or hepatic impairment—risk of fatal toxicity 1, 3, 4
• Do not initiate colchicine after 36 hours from gout symptom onset—efficacy declines sharply 1, 2, 3
• Do not stop colchicine during acute gout flare if patient is already on prophylactic therapy—continue and treat flare separately 1
• Do not discontinue prophylaxis early when starting urate-lowering therapy—premature cessation doubles flare rates 1
• Do not use colchicine in severe renal impairment (CrCl <30 mL/min) without extreme caution and dose reduction to 0.3 mg once daily maximum 2, 3

---

Safety Profile

Gastrointestinal Adverse Effects

• Low-dose regimen (1.8 mg total): 23–26% experience GI toxicity, primarily diarrhea 1
• High-dose regimen (4.8 mg): 77–100% experience severe diarrhea 1

Serious Toxicity

• Colchicine has a narrow therapeutic index 4, 8
• Lowest reported lethal oral doses: 7–26 mg 4
• High fatality rate after acute ingestions exceeding 0.5 mg/kg 4
• Toxicity presents in three phases: (1) GI phase 10–24 hours post-ingestion; (2) multi-organ dysfunction 24 hours to 7 days; (3) recovery over weeks 4

Monitoring Requirements

• Monitor CBC, liver enzymes, and CPK regularly, especially in FMF patients 5
• Monitor for signs of neurotoxicity and myotoxicity, particularly with concurrent statin use or renal impairment 2